European NfG Update? [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2005-09-20 16:58 (6763 d 22:36 ago) – Posting: # 33
Views: 10,122

There have been rumors during last week's IIR's 'Dissolution, Biovailability & Bioequivalence 2005' conference in Amsterdam about a planned Update of the European NfG (Note for Guidance) on the Investigation of Bioavailability and Bioequivalence (CPMP/EWP/QWP/1401/98).

Potential candidates for a change are:
3.1 Design
where for HVDs a steady-state study in order to reduce variability may not be acceptable any more. A replicate design should be considered instead.
A maximum number of subjects (e.g., n=40 as in New Zealand’s Guideline) is also under discussion.
3.6.2 Acceptance range for pharmacokinetic parameters
which according to the current NfG may be widened from 0.8–1.25 if prospectively defined and justified based on clinical grounds (i.e., safety or efficacy concerns for patients switched between formulations). This procedure provoced a good deal of discussions between applicants and regulators; dropping the widened acceptance range would lead to harmonization with the FDA, where not exceptions are allowed.

Hopefully, the picture will be sharpened next month at the Bio-International 2005 in London.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,639 registered users;
83 visitors (0 registered, 83 guests [including 8 identified bots]).
Forum time: 14:34 CET (Europe/Vienna)

Nothing shows a lack of mathematical education more
than an overly precise calculation.    Carl Friedrich Gauß

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5